Artivion, Inc. (NYSE:AORT) SVP Sells $307,263.24 in Stock

Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Marshall S. Stanton sold 10,548 shares of the business's stock in a transaction dated Friday, May 9th. The shares were sold at an average price of $29.13, for a total transaction of $307,263.24. Following the completion of the transaction, the senior vice president now directly owns 105,332 shares of the company's stock, valued at $3,068,321.16. The trade was a 9.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Artivion Stock Down 0.4%

NYSE:AORT traded down $0.12 during trading hours on Thursday, hitting $28.86. The stock had a trading volume of 62,568 shares, compared to its average volume of 317,821. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $32.33. The business has a 50 day simple moving average of $24.32 and a two-hundred day simple moving average of $27.25. The company has a market cap of $1.23 billion, a PE ratio of -1,443.00 and a beta of 1.54.

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.06). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The firm had revenue of $98.98 million during the quarter, compared to analyst estimates of $94.81 million. Analysts predict that Artivion, Inc. will post 0.37 EPS for the current year.

Hedge Funds Weigh In On Artivion

Several institutional investors and hedge funds have recently made changes to their positions in AORT. Barclays PLC boosted its stake in shares of Artivion by 346.3% during the 3rd quarter. Barclays PLC now owns 70,877 shares of the company's stock valued at $1,888,000 after buying an additional 54,996 shares during the last quarter. Franklin Resources Inc. lifted its stake in Artivion by 14.4% during the third quarter. Franklin Resources Inc. now owns 21,107 shares of the company's stock worth $553,000 after purchasing an additional 2,663 shares during the last quarter. JPMorgan Chase & Co. increased its position in Artivion by 394.9% in the third quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company's stock worth $2,606,000 after buying an additional 78,120 shares during the period. GAMMA Investing LLC increased its position in Artivion by 21.8% in the fourth quarter. GAMMA Investing LLC now owns 2,772 shares of the company's stock worth $79,000 after buying an additional 497 shares during the period. Finally, KBC Group NV increased its position in Artivion by 80.4% in the fourth quarter. KBC Group NV now owns 2,813 shares of the company's stock worth $80,000 after buying an additional 1,254 shares during the period. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on AORT. Citizens Jmp raised shares of Artivion to a "strong-buy" rating in a research note on Tuesday, May 6th. JMP Securities reissued a "market outperform" rating and set a $33.00 target price on shares of Artivion in a research report on Tuesday, May 6th. Needham & Company LLC reissued a "buy" rating and set a $32.00 target price on shares of Artivion in a research report on Tuesday, May 6th. Finally, Stifel Nicolaus dropped their target price on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.